CORD-19:867ebb2be2d466bcb35e5a7319708eaff39c4799 / 334748-334927
Annnotations
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T375","span":{"begin":0,"end":11},"obj":"Sentence"},{"id":"T376","span":{"begin":12,"end":179},"obj":"Sentence"}],"text":"Conclusion: Cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates."}
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"T46910","span":{"begin":0,"end":11},"obj":"Sentence"},{"id":"T74889","span":{"begin":12,"end":179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conclusion: Cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates."}
Epistemic_Statements
{"project":"Epistemic_Statements","denotations":[{"id":"T542","span":{"begin":0,"end":179},"obj":"Epistemic_statement"}],"text":"Conclusion: Cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates."}
CORD-19-PD-MONDO
{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1678","span":{"begin":165,"end":169},"obj":"Disease"},{"id":"T62251","span":{"begin":165,"end":169},"obj":"Disease"}],"attributes":[{"id":"A1678","pred":"mondo_id","subj":"T1678","obj":"http://purl.obolibrary.org/obo/MONDO_0100073"},{"id":"A27389","pred":"mondo_id","subj":"T62251","obj":"http://purl.obolibrary.org/obo/MONDO_0100073"}],"text":"Conclusion: Cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates."}